Sell-Side vs Buy-Side Advisory in Healthcare Deals: Who Represents Whom in 2026
A sell-side advisor represents the owner selling a healthcare practice or company. A buy-side advisor represents the acquirer. Each one owes loyalty only to the client that pays it. If a buyer approached you first, the advisor working that deal already works for the buyer. In calendar 2025, PESP tracked 664 add-ons among 1,029 PE healthcare deals. Most practice sellers sit across from a buyer that has done this many times before. The practical question is whether a competitive process or experienced deal counsel will earn back what it costs you. The tables below answer that by specialty, deal size and number of buyers.
Data as of November 20, 2026. Figures marked (our arithmetic) are our calculations on the cited sources, with assumptions stated.
Sell-Side vs Buy-Side in 2026: Who Each Advisor Works For
Both advisors do the same technical work: valuation, buyer or target lists, diligence and negotiation. The difference is the client. The sell-side advisor succeeds when your practice sells on terms you accept. The buy-side advisor succeeds when its client buys a practice like yours on terms the client likes. Neither one is neutral.
Sell-side vs buy-side advisory in healthcare deals: mandate, work, pay and conflicts
| Dimension | Sell-side advisor | Buy-side advisor | What a physician owner should ask |
|---|---|---|---|
| Client | The practice owner or owners selling | The PE platform, health system, family office or strategic buyer | "If my interests and the buyer's split, whose side are you on?" |
| Typical trigger | Retirement, partner buyout, an inbound offer, payer pressure, a need for capital | A platform's add-on plan, a system entering a new market | "Did the buyer approach me as part of a roll-up plan in my market?" |
| Core work | Preparing financials, positioning the practice, contacting buyers, managing bids, negotiating the LOI and purchase agreement | Screening targets, valuation, diligence, financing, integration planning | "Who on your team has run a physician practice sale, not just a corporate deal?" |
| Deliverables | Teaser, confidential information memorandum, data room, bid comparison | Target screen, diligence findings, financing package, offer structure | "Can I see a redacted example of your CIM and bid comparison?" |
| How commonly paid | Retainer plus a success fee at closing, with the base and trigger negotiated | Retainer, hourly or project fees, sometimes a fee on completed acquisitions. Many platforms use salaried in-house corporate development staff instead | "What exactly triggers your fee, and what value is it calculated on?" |
| Built-in conflict | A success fee rewards closing, and repeat relationships with the same buyers can soften negotiation | A completion fee rewards closing even when walking away would serve the buyer better | "Which buyers have you sold to, or represented, more than once?" |
| Regulatory role | Flags healthcare regulatory issues during preparation and works alongside the seller's counsel | Screens targets for the same issues and plans deal timing around regulatory review | "When does healthcare regulatory counsel get involved, and who hires them?" |
| When an owner might skip one | A single logical buyer, a small internal sale to partners | Platforms with in-house corporate development teams | "If I skip a sell-side advisor, who replaces that experience on my side?" |
The other side of the table is large. More than four in five U.S. physicians (82.0%) were employed by hospitals or corporate entities such as PE firms or insurers as of January 1, 2026, according to PAI-Avalere data reported by Axia Growth. Hospitals employed 59.7% and corporate entities 22.3%. That leaves about 18.0% outside those two groups (our arithmetic on rounded source figures). The same source reports that hospitals and corporate entities owned 157,200 physician practices, 63.9% of the total, with corporate ownership (33.2%) ahead of hospital ownership (30.6%). The two shares sum to 63.8% because each is rounded. An independent owner sells into a market of experienced buyers.
Those buyers keep coming because the spending base keeps growing. Per the CMS National Health Expenditure fact sheet, physician and clinical services spending grew 8.1% to $1,109.7 billion in 2024, and CMS projects it to grow 5.5% a year on average from 2025 to 2034. Buyers still cite payer pressure as the reason to sell now. Reimbursement pressure is real at the practice level, and in a negotiation it also becomes a reason to pay you less. Give your advisor your own payer contract terms and renewal dates before you accept that argument.
What each side does at each stage
| Deal stage | Sell-side work for the owner | Buy-side work for the acquirer | Where owners lose value without help |
|---|---|---|---|
| Preparation | Normalize EBITDA, clean up provider pay and owner add-backs, build the data room | Build the target list, model the add-on at the platform's integration cost | Add-backs left undocumented get cut in diligence |
| Outreach | Contact several buyers under NDA at the same time | Approach owners one at a time, often before they have an advisor | A single bidder sets the pace and the price |
| Indications and LOI | Compare bids on cash at close, contingent value and terms | Write an LOI that locks exclusivity early and leaves key definitions open | Earnout and working capital terms left vague until after exclusivity |
| Diligence | Run a seller quality-of-earnings review before buyers do | Commission quality of earnings and look for reasons to lower the price | Price reductions late in the process with no competing bid in reserve |
| Purchase agreement | Negotiate escrow, indemnity caps, survival periods and RWI | Draft the first version of every document | The first draft becomes the base for every later change |
| Post-closing | Track earnout reporting and escrow release dates | Run integration and measure the earnout | Earnout targets missed because of decisions the buyer controls |
The relationship conflict. Every guide mentions the fee conflict. The relationship conflict is harder to see. PESP's review reports 664 add-ons and 420 platform companies for 2025 as totals, not deals per platform, so a repeat-buyer rate cannot be calculated from it. The structure is still plain. An acquisitive platform comes back to market again and again, and a physician usually sells once. A banker who sells to the same platform year after year has a reason to keep it happy, and no fee disclosure will show that. Our guide to choosing a healthcare investment banker covers the vetting process.
Which kind of representation fits your situation
| Your situation | Representation that usually fits | Why |
|---|---|---|
| Three or more plausible buyers, practice EBITDA above about $1 million | Sell-side advisor running a structured process | Competition has something to work on, and the size bands below reward getting to a better buyer |
| One logical buyer, such as a hospital system that already employs most of the group | Experienced healthcare deal counsel plus an independent accountant | There is no auction to run. The work is negotiation and documents |
| Small practice priced near asset value | Deal counsel and an accountant, sometimes a practice broker | Fees on a large-firm scale rarely pay back on a small deal |
| Partner buyout inside the group | Separate counsel for buyer and seller partners, one shared valuation | The parties know each other. The risk is the documents, not the market |
| Your practice is the acquirer, buying a retiring colleague or a second location | A buy-side advisor or accountant for valuation and diligence, plus deal counsel | You now carry the buyer's diligence risk |
| Raising minority capital instead of selling control | A placement agent or capital advisor, plus counsel | Minority capital brings different investors, documents and rules. Our capital raising guide covers them |
How Sell-Side Fees Work: The Base Matters as Much as the Rate
Rates are negotiated deal by deal. What an owner controls is the structure. Four terms decide what the advisor actually collects: the retainer and whether it is credited against the success fee, the success fee rate, the value the rate applies to, and when that value is measured.
Worked example, our arithmetic. The 3.5% rate and the fee structure are illustrative, not market norms. Engagement letters define purchase price and fee triggers in different ways. The deal is Offer B from the dermatology example below: an $11.50 million headline enterprise value that includes $1.15 million of rolled equity and a $0.50 million maximum earnout. Fee bases are measured on enterprise value, before debt repayment and seller costs.
| Fee base | Base value ($M) | Fee at 3.5% | When paid |
|---|---|---|---|
| Full headline, including rollover and maximum earnout | 11.50 | $402,500 | At closing |
| Headline minus rollover minus maximum earnout (escrow stays in the base) | 9.85 | $344,750 | At closing |
| Earnout payments and rollover sale proceeds | What the seller actually receives | 3.5% of amounts received | When the earnout pays or the rolled equity is sold |
The narrower base cuts the closing fee by $57,750 in this example (our arithmetic: $402,500 minus $344,750). The advisor still earns 3.5% on the rollover and earnout, but only on cash the seller actually collects. Part of the advisor's pay then depends on the same outcome the seller lives with. The gap grows with the size of the rollover and earnout.
A seller-friendly fee clause reads roughly like this in plain terms: "The success fee equals 3.5% of the purchase price paid at closing, including amounts placed in escrow. On any earnout payment or sale of rolled equity, the advisor receives 3.5% of the cash the seller actually receives, payable within 30 days of receipt. Retainers paid are credited in full against the success fee." The business point is that every dollar of fee follows a dollar of value you either receive at closing or collect later.
For how retainers and success fees are built in general, see what healthcare investment banking is.
Why 664 Add-On Deals in 2025 Changed the Seller's Math
PESP's Private Equity Healthcare Deals: 2025 in Review tracked 1,029 PE-backed healthcare deals in calendar 2025: 151 leveraged buyouts, 664 add-on acquisitions and 214 growth investments, involving 420 platform companies and 708 investment firms. PESP built the count from PitchBook and LevinPro HC data and says the final count is likely an underestimate. Read 664 as a floor, not a total. The private equity physician roll-ups guide charts how these platforms grow.
Add-on share of tracked PE healthcare deals, calendar 2025
| Segment | Add-ons | Total tracked deals | Add-on share |
|---|---|---|---|
| All PE healthcare deals (PESP 2025 in Review) | 664 | 1,029 | 64.5% (our arithmetic: 664 ÷ 1,029) |
| Outpatient care (Becker's ASC Review on PESP 2025 data) | 119 | 148 | 80.4% (our arithmetic: 119 ÷ 148) |
| Dental care (PESP 2025 in Review) | About 142 (our arithmetic: 95% × 149, with PESP's 95% rounded) | 149 | 95%, all made by PE-owned platforms (PESP-reported share) |
The add-on share rises the closer you get to physician and dental practices: about two in three of all tracked deals, four in five in outpatient care and 95% in dental. PESP also reported that ten of the 18 platform companies with the most deals in 2025 were dental care companies.
| What PESP's 2025 counts show | What they cannot show |
|---|---|
| Most tracked PE healthcare deals were add-ons | Who the buyer is in your deal |
| Add-on shares were highest in outpatient and dental care | How many prior deals your buyer has closed |
| 420 platforms and 708 investment firms took part | How deals were spread across them |
| Where volume concentrated nationally | Prices, multiples or terms |
Add-on vs platform pricing. The add-on label sets the price range. Sikich's Q3 2026 healthcare M&A update reports that physician practice platforms command a four- to eight-turn premium over add-on practices. In dental it puts DSO platforms at 9x to 11x EBITDA and add-ons at 5x to 8x. Its separate band for individual dental practices (5x to 9x) overlaps the add-on band almost entirely, so the gap that matters is platform against everything else. Sikich reports dental practice pricing steady for two years.
Indicative physician practice EV/EBITDA by practice EBITDA (Sikich, Q3 2026)
| Practice EBITDA | Indicative EV/EBITDA |
|---|---|
| Below $1 million | 5x to 7x |
| $1 million to $3 million | 7x to 9x |
| $3 million to $5 million | 9x to 11x |
| Above $5 million | 11x to 13x |
Two other datasets show the same size effect. Each measures a different population and method, so read each on its own terms. Their ranges are not directly comparable to Sikich's bands or to each other.
Closed small-business sales in the healthcare sector, median multiple by size (Axia Growth analysis of 4,554 closed small-business sales over $500K across sectors, healthcare rows shown, data as of October 28, 2026)
| Size band | Deals | Median multiple | Middle half | Earnings basis |
|---|---|---|---|---|
| Under $500K SDE | 182 | 3.4x | 2.7x to 4.2x | SDE |
| $500K to $1M SDE | 42 | 3.4x | 2.5x to 4.4x | SDE |
| $1M to $2M SDE | 22 | 3.3x | 2.7x to 7.5x | SDE |
| $2M to $3M EBITDA | 13 | 5.1x | 3.1x to 10.9x | EBITDA |
| $3M to $5M EBITDA | Not reported by Axia | |||
| $5M to $10M EBITDA | 14 | 8.8x | 3.4x to 10.7x | EBITDA |
| $10M+ EBITDA | 17 | 12.9x | 9.4x to 18.5x | EBITDA |
SDE (seller's discretionary earnings) adds back the owner's own pay, so an SDE multiple is not comparable to an EBITDA multiple. Every band above $500K rests on fewer than 50 deals, and the wide middle-half ranges reflect that.
BuckheadFMV's benchmarks cover 187 U.S. healthcare services control transactions announced January 2023 through October 2026, priced from SEC, state and bankruptcy court filings. Deals below $10 million traded at a median 2.8x EBITDA and 0.27x revenue. Deals above $200 million traded at 11.2x EBITDA and 1.34x revenue. BuckheadFMV notes that its EBITDA medians lean toward larger deals because small private sellers rarely disclose EBITDA.
A platform that buys you as an add-on pays an add-on multiple for your earnings and plans to sell them later inside a business valued at a platform multiple. That spread is one source of the buyer's planned return. Growth, debt, integration costs and the eventual exit price all move the final result. A sell-side advisor's job is to win some of the spread back through competition.
Who you are talking to. In dental and outpatient care, PE buyers are often platforms buying add-ons, but national counts cannot tell you about your buyer. Confirm its experience directly. Ask for its announced acquisitions over the past 24 months and who advised it on them. An experienced platform arrives with a corporate development team or retained buy-side advisor, a standard LOI, a diligence list, a quality-of-earnings firm, and counsel who have drafted rollover and earnout terms many times. Most physician owners negotiate one practice sale in a career, so the experience gap runs one way. A sell-side advisor puts comparable experience on your side and gets other buyers looking at the practice before exclusivity starts. Our reverse due diligence guide lists the questions to ask.
Representation by Specialty: Where a Process Pays and Where It Does Not
The right advisor depends on how many buyers price your earnings and how they price them. Deal counts below are national 2025 PE counts. Multiples come from different datasets and populations, labeled in each row, so compare within a row, not across rows.
| Specialty | Buyer activity (source, period) | Pricing reference (source, population) | Representation that usually fits |
|---|---|---|---|
| Dermatology | 24 PE outpatient deals, the most of any outpatient subsector (Becker's ASC Review on PESP, 2025) | Physician practice bands by EBITDA (Sikich, Q3 2026) | Sell-side process once EBITDA clears about $1 million and three or more distinct buyers remain |
| Eye care | 22 PE outpatient deals (Becker's ASC Review on PESP, 2025) | Physician practice bands by EBITDA (Sikich, Q3 2026) | Same as dermatology |
| Dental | 149 PE deals, 95% add-ons by PE-owned platforms (PESP, 2025) | DSO platforms 9x to 11x, add-ons 5x to 8x, practices 5x to 9x EBITDA (Sikich, Q3 2026) | Sell-side process for multi-location groups. Single practices often sell well with a dental-focused broker and counsel |
| Oncology | 9 PE outpatient deals (Becker's ASC Review on PESP, 2025) | Physician practice bands by EBITDA (Sikich, Q3 2026) | Advisor focused on structure and documents. Competition is thin, so terms carry more value than the auction |
| Primary care | Hospital purchases of individual practices are common in BuckheadFMV's filings data | Median 0.11x revenue for primary care practices, hospital purchases clustering at 0.05x to 0.15x revenue (BuckheadFMV, January 2023 to October 2026, largely West Virginia filings) | Counsel and an accountant when only a hospital is interested. Test for an earnings buyer first |
| Ambulatory surgery centers | 148 PE outpatient deals overall (PESP, 2025), no ASC-specific count | Single-specialty 5x to 8x, multispecialty 6x to 10x, regional operators 11x to 17x EBITDA. Median ASC multiple 7.9x in 2025 (Sikich, Q3 2026) | Sell-side process, with physician syndication and hospital partner rights mapped first |
| Home health and hospice | No 2025 count in these sources | Small agencies typically mid-single digits, Enhabit take-private at 10.2x. Fewer closings and buyers discounting billing and compliance risk (Sikich, Q3 2026) | Advisor who can run a billing and compliance review before buyers do |
| Urgent care | No 2025 count in these sources | 3x to 7x EBITDA under $10 million of revenue, 6x to 11x at $10 million to $50 million (Sikich, Q3 2026) | Sell-side process for multi-site operators. Single sites often have one logical regional buyer |
| Behavioral health | 56 PE deals (PESP, 2025) | No practice-level band in these sources | Advisor with behavioral payer and licensing experience |
Two short cases outside dermatology
Illustrative. Practice figures are hypothetical. Multiples are the sourced bands above. All calculations are our arithmetic.
Primary care: is anyone buying the earnings? A primary care group has $3.0 million of revenue and $0.6 million of EBITDA. A local hospital offers to buy it. At BuckheadFMV's 0.05x to 0.15x revenue cluster for hospital purchases of individual primary care practices, the price lands at $0.15 million to $0.45 million, which BuckheadFMV reads as pricing for equipment and records rather than goodwill. If an earnings buyer such as a PE-backed primary care platform exists, Sikich's below-$1 million band of 5x to 7x implies $3.0 million to $4.2 million. The two methods describe different buyers, and the gap is the whole decision. Spend a small fixed budget testing for an earnings buyer before you price the deal. If none exists, size representation to an asset-value deal.
Oncology: one buyer, so terms carry the value. An oncology group with $4.0 million of EBITDA hears from one platform. Sikich's $3 million to $5 million band of 9x to 11x implies $36 million to $44 million of enterprise value. With nine tracked PE outpatient oncology deals nationally in 2025, a local auction may produce one or two bidders at most. The advisor's value moves from price competition to structure. SRS Acquiom found earnouts in 30% of 2025 private-target deals valued at $50 million or less. On a $40 million deal, each 1% of price shifted from escrow or earnout back to cash at close is $0.4 million (our arithmetic). A negotiator who knows what a platform will concede on earnout definitions and escrow size earns the fee there.
Who Exits Your Rollover: Sponsor-to-Sponsor Sales
Rolled equity turns into cash when the platform itself sells. The buyer of that platform is usually another sponsor.
| Measure, 2025 | Figure | Source and population |
|---|---|---|
| Healthcare PE buyouts announced | 445, second most on record | Bain & Company, Global Healthcare PE Report 2026 release, global |
| Sponsor-to-sponsor deal value | More than $120 billion, Bain estimate | Same Bain release, global |
| Sponsor-to-sponsor deals above $1 billion | More than 30, up from 8 in 2024 | Same Bain release, global |
| Sponsor-to-sponsor share of large North American deals | More than 70% | Same Bain release, large North American healthcare PE deals |
These are large-deal figures, not practice sales. They matter to a practice seller for one reason: they describe the exit your rollover depends on. Ask the platform who it expects to sell to, on what timeline, and why that buyer will pay a higher multiple than the platform paid for you. Then ask what happens to your rolled equity if the platform sells at a lower multiple. PitchBook data reported by Sikich shows the median healthcare M&A multiple falling from 14.5x EV/EBITDA in 2024 to 13x in 2025 and 11.6x for 2026 year to date as of Sikich's Q3 2026 update. A platform bought at a peak multiple and sold into a softer market can return less than the closing value of your rollover.
Earnouts, Escrows and Indemnity: The Terms the Buyer's Side Drafts
Headline price gets the attention. Deferred and contingent terms decide what you take home. The figures below come from SRS Acquiom's two 2026 studies of private-target deals in its own dataset, mostly 2025 deals, across all industries unless a row says otherwise. They are market reference points, not physician practice norms.
Private-target deal terms (SRS Acquiom 2026 earnout study and 2026 escrow study)
| Term | Figure | What it means for a practice seller |
|---|---|---|
| Earnouts, 2025 deals excluding life sciences | 24% | One deal in four ties part of the price to future results |
| Earnouts, 2025 healthcare services targets | 37%, vs 26% in 2014 to 2022 | Healthcare services sellers see earnouts more often than the wider market |
| Earnouts, 2025 deals by U.S. private equity buyers | 24%, vs 13% in 2014 to 2022 | PE buyers use earnouts far more than they did |
| Earnouts, 2025 deals of $50 million or less | 30% | Smaller deals carry more contingent pay |
| Earnout payout, lower middle-market deals with any achievement | Median 43 cents on the dollar | Among earnouts that paid something, the typical small deal paid less than half |
| Earnout payout, deals with more than $50 million upfront and any achievement | Median 67 cents on the dollar | Larger sellers collect more of what they negotiated |
| Total escrow, 2025 deals with reps and warranties insurance (RWI) | Average 5.1%, median 2.8% of transaction value | RWI shrinks the cash the buyer holds back |
| Total escrow, 2025 deals without RWI | Average 14.7%, median 11.1% | Without RWI, expect about a tenth of the price held back |
| General indemnity escrow, 2025, with RWI vs without | Median 0.5% vs 10.0% | The biggest single swing in holdback size |
| Purchase price adjustment mechanism, 2025 | 93% of deals, and 89% of those had an adjustment | Treat the working capital target as part of the price |
| Indemnification claims, excluding price adjustments | 28% of all deals, 33% of deals with RWI | Claims are common, so escrow terms and survival periods matter |
The buy-side brief is to move value out of cash at close and into these terms, where the buyer controls the drivers. The sell-side brief is to move it back. A seller negotiating alone tends to focus on the multiple. The earnout EBITDA definition, the working capital peg, the escrow size and release dates, and who pays for RWI often move more money.
Worked Example: A Dermatology Owner Comparing Two Offers
Illustrative. The owner, offers, probabilities, discount rates and dollar figures are hypothetical. The PESP and Becker's deal counts, Sikich multiple bands and SRS Acquiom terms are sourced above. All calculations are our arithmetic.
A dermatology group with $1.5 million of EBITDA receives an unsolicited letter from a PE-backed dermatology platform. The letter names a headline price and asks for a short exclusivity window once an LOI is signed. Dermatology led tracked outpatient PE deals in 2025, so the owner confirms the platform's announced deals, then runs the local buyer count below and finds four distinct, plausible buyers.
- Path A: negotiate directly. Faster, no advisory fee, no competing offer. The platform sets the pace, the diligence list and the first draft of every document.
- Path B: hire a sell-side advisor. The advisor approaches the other buyers before exclusivity. The costs are time, sharing data with competitors under NDA, and the fee.
Assumptions. - Headline is the buyer's stated enterprise value. It counts rolled equity at the buyer's closing value and the earnout at its undiscounted maximum. Neither is an expected value. - Escrow is 5% of headline. That sits between SRS Acquiom's 2025 median total escrow with RWI (2.8%) and without (11.1%). Sizing it on headline is a simplification. Escrows are usually sized on cash consideration, so this slightly overstates the holdback, most of all for Offer A with its larger rollover. - Debt repaid at closing is $0.80 million and counsel and accounting cost $0.30 million in both offers. - Offer B's advisor is paid 3.5% at closing on headline minus rollover minus maximum earnout ($9.85 million × 3.5% = $344,750), plus 3.5% of whatever the seller later receives from the earnout and rollover. Offer A has no advisor. - All figures are pre-tax.
Step 1: cash at close, $ millions
| Line item | Offer A (direct) | Offer B (via advisor) |
|---|---|---|
| Headline price | 12.00 | 11.50 |
| Implied multiple of $1.5 million EBITDA | 8.0x | 7.7x |
| Less rolled equity, at closing value | 2.40 | 1.15 |
| Less earnout, at maximum | 1.50 | 0.50 |
| Less escrow, 5% of headline | 0.60 | 0.58 (0.575 unrounded) |
| Less debt repaid at closing | 0.80 | 0.80 |
| Less counsel and accounting | 0.30 | 0.30 |
| Less advisory fee at closing | 0.00 | 0.34 (0.345 unrounded) |
| Total deductions | 5.60 | 3.67 |
| Cash at close | 6.40 | 7.83 |
| Cash at close as share of headline | 53% | 68% |
| Headline value not paid at close (rollover plus maximum earnout plus escrow) | 4.50 | 2.23 |
Offer B check: 11.50 minus 1.15, 0.50, 0.575, 0.80, 0.30 and 0.345 equals 7.83. Both headlines sit inside Sikich's 7x to 9x band for practices with $1 million to $3 million of EBITDA. Offer A wins on the multiple. Offer B pays $1.43 million more at closing and leaves about half as much headline value deferred or contingent. The last row is face value, not expected value. Step 2 puts outcomes on those pieces.
Step 2: pre-tax total received across outcomes, undiscounted, $ millions
Each scenario adds the escrow, released in full, plus the earnout and rollover payouts to cash at close. Offer B totals are net of the advisor's 3.5% on earnout and rollover proceeds. The middle case uses SRS Acquiom's 43-cent median for lower middle-market earnouts. That median counts only deals where the earnout paid something, so using it as the middle case likely overstates a typical outcome once zero payouts are included. The downside case covers a zero payout. The scenario probabilities are our assumption, not market data, and the results below are only as reliable as those assumptions.
| Scenario | Probability (assumed) | Earnout paid | Rollover value at exit vs closing value | Offer A | Offer B | Higher |
|---|---|---|---|---|---|---|
| Downside | 25% | 0% | 0.5x | 8.20 | 8.96 | B by 0.76 |
| Middle | 50% | 43% | 1.0x | 10.05 | 9.72 | A by 0.32 |
| Upside | 25% | 100% | 2.0x | 13.30 | 11.11 | A by 2.19 |
| Probability-weighted | 46.5% expected | 1.125x expected | 10.40 | 9.88 | A by 0.52 |
Offer A middle case, for reference: 6.40 cash + 0.60 escrow + 0.645 earnout (43% of 1.50) + 2.40 rollover = 10.045. Offer B middle case: 7.83 cash + 0.575 escrow + (0.215 earnout + 1.15 rollover) × 0.965 after the advisor's 3.5% = 9.72.
Step 3: probability-weighted present value at different discount rates, $ millions
Timing assumptions: the escrow releases at the end of year one, the earnout pays at the end of year two and the rollover is realized at the end of year five.
| Annual discount rate | Offer A | Offer B | Higher |
|---|---|---|---|
| 0% (Step 2 total) | 10.40 | 9.88 | A by 0.52 |
| 8% | 9.39 | 9.40 | About even |
| 12% | 9.02 | 9.23 | B by 0.21 |
| 16% | 8.72 | 9.09 | B by 0.37 |
Components are rounded, so totals and differences can be off by 0.01.
What the numbers say. Under these assumed probabilities and timing, the two offers break even at a discount rate between 7% and 8% a year (our arithmetic). Treat that as an illustration of how to compare offers, not a market finding. Below that, Offer A's larger rollover and earnout carry it. Above it, Offer B's extra $1.43 million at closing wins. A rollover in a single PE platform's equity carries more risk than a diversified portfolio, so many owners would apply a rate well above 8%. Offer B also wins outright whenever the rollover disappoints. Offer A wins when the platform exits well and the owner can wait five years for it. The choice turns on the owner's view of the platform's exit, the discount rate and the owner's need for cash now, not on the headline multiple. Tax treatment of rollover, earnout and cash depends on deal structure and can shift the ranking. Have your accountant rerun Steps 2 and 3 after tax before you choose.
- Rolled equity pays when the platform sells, on the sponsor's timeline. Model it in the rollover equity calculator.
- The earnout depends on targets the buyer controls through staffing, payer contracts and scheduling. Fix definitions, measurement periods and start dates in the LOI. The earnout value calculator puts a present value on each offer's contingent piece.
Compare post-closing physician pay too. Employment terms can outweigh a headline gap over several years, so get them from each buyer before you choose. Run your own figures through the deal proceeds calculator.
How to Count Local Buyers Before You Hire Anyone
National counts have no state breakout and no count of distinct buyers. Twenty-four dermatology deals could reflect many platforms or a few very active ones.
- Ask every banker who pitches you to name the acquirers that closed deals in your specialty and state over the past 24 months, with links to the announcements. A vague answer means the buyer list in the pitch is generic.
- Collapse the list to distinct buyers. Two platforms owned by the same PE firm count as one. So do a platform and its own add-ons, because they will not bid against each other.
- Strike buyers that already own a competitor next door, buyers whose footprint ends far from you, and buyers that rarely work with your payer mix or referral base.
- Count what remains. Three or more distinct, plausible buyers support a competitive process. With one or two, the advisor's job shifts to structure and documents.
Put the Buyer's Promises in Writing Before the LOI
A practice buyer's return depends on physicians staying productive after closing. That gives the seller bargaining power before closing on governance, autonomy and pay. The standard reassurance is that nothing will change for patients or staff. That promise is worth only what the documents say. Convert it into terms: clinical autonomy language, staffing minimums, scheduling control, and governance rights such as a board seat or approval over clinical policy. A buyer that will not write it down has told you something. Healthcare deal structures covers rollover and governance terms, and the LOI red flags checklist shows what to catch before exclusivity.
Pre-LOI checklist for the seller:
- Earnout metric, definition of EBITDA or revenue, measurement period and who controls the inputs
- Working capital target and how it was calculated
- Escrow size, release dates and whether the buyer will buy RWI
- How long your general reps survive after closing and the cap on claims against you
- Rollover percentage, the class of equity you receive and what happens to it if you leave
- Physician compensation, term, and non-compete scope after closing
- Exclusivity length and what ends it early
- Which assets the price depends on: real estate, a satellite location, a service line, the practice name
- If you keep the building and lease it to the buyer, the rent, term and renewal options, set in the LOI rather than after it
Family Office and Investor-Group Buyers: Allocators vs Syndicators
PESP counted 708 investment firms in its 2025 deals but not whose money sat behind each check. Family offices and physician investor groups also buy and co-invest in practices. Some invest only their own capital. Others syndicate and raise most of the check after signing with you, which affects timing and certainty and can reopen terms.
Ask one question: "Is this your capital, and does anyone else have to approve before you can close?" Then check the answer. SEC EDGAR full-text search is free and shows public notices that private issuers file when they raise capital. Repeated capital-raising filings by a buyer's affiliated entities around its acquisitions can be a sign it raises outside money deal by deal. Ask your attorney what the filings mean for your deal. If part of the check depends on others, have the LOI state how much is the sponsor's own and any financing condition. Family office advisors negotiate structure as hard as price, so compare every offer on cash at close and on discounted total value, as in the example above. How family offices invest in healthcare covers their structures.
Hospital and Health System Transactions Through Q3 2026
| Period | Hospital and health system transactions announced | Source |
|---|---|---|
| Q1 2026 | 22 | Becker's Hospital Review on Kaufman Hall data |
| Q2 2026 | 18 | Same |
| Q3 2026 | 16 | Same |
| Q1 to Q3 2026 | 56 (our arithmetic) | Sum of the above |
The quarterly count fell from Q1 to Q3, yet Becker's reports 2026 on pace for the busiest hospital M&A year since the pandemic, with megamergers driving the activity. Kaufman Hall's Q3 2026 release (Oct 13, 2026) reported $8.2 billion of transacted revenue in the quarter and an average seller size of nearly $586 million, which Kaufman Hall attributes to continued participation by larger organizations. The year is busy, and it is busy at the large end. That fits the national spending picture: hospital spending grew 8.9% to $1,634.7 billion in 2024, per the CMS NHE fact sheet.
For a physician group, the risk sits inside those combinations. When a system sells or merges a hospital, service line or employed group, its sell-side advisor works for the system, not for you. Pull every directorship, call coverage and service agreement, along with assignment, non-compete and change-of-control clauses, and map which ones survive a new owner. A new owner will review each of those payments and may restructure or end them. The healthcare compliance due diligence guide explains why these arrangements get close attention.
Building the Seller's Deal Team: Who to Hire, and When
An active platform arrives with its team already assembled. Most practice owners assemble theirs after the first letter arrives, which hands the buyer the pace. Match each role on your side to its counterpart across the table, and bring each one in before the point where the buyer's version starts setting terms.
| Role on your side | Bring in before | What they do for you | Buyer's counterpart |
|---|---|---|---|
| Sell-side advisor (or experienced deal counsel when there is one logical buyer) | You reply to an unsolicited offer or sign an NDA | Counts local buyers, runs outreach, compares bids on cash at close and contingent value | Corporate development team or retained buy-side advisor |
| Healthcare deal counsel | You sign an LOI with exclusivity | Reviews LOI definitions, marks up the purchase agreement, reviews leases, directorships and rollover terms | Buyer's deal counsel, who drafts first |
| Accountant or quality-of-earnings provider | Outreach begins | Documents add-backs, runs a seller quality-of-earnings review, models each offer after tax | Buyer's quality-of-earnings firm |
| Personal financial or tax planner | You compare LOIs | Sets your discount rate and cash needs, sizes how much rollover concentration you can carry | None. This role exists only on your side |
| Employment counsel for each physician | The first draft of employment agreements | Reviews compensation, term, autonomy language and non-compete scope | Buyer's HR and employment counsel |
Using the dermatology example. In Offer A, $4.50 million of the $12.00 million headline is not paid at close. The planner's discount rate decides whether that deferred value beats Offer B's extra $1.43 million at closing, and the accountant's after-tax rerun can change the answer. Counsel's work on the earnout definition and escrow size decides how much of the $4.50 million you actually collect. The advisor's job is to have Offer B on the table at all. Each role moves a different line in Steps 1 to 3, which is why skipping one rarely saves what it appears to.
Sequence before exclusivity:
- Engage the accountant and start documenting add-backs.
- Run the local buyer count and decide between a sell-side process and counsel-led negotiation.
- Engage healthcare deal counsel and confirm who coordinates regulatory questions.
- Set your discount rate and minimum cash at close with your planner.
- Only then sign an LOI with exclusivity.
Regulatory areas to raise before the LOI
Healthcare deals carry regulatory questions that can change structure, timing or price. Have your attorney review each of these for your deal before you sign an LOI.
- Federal antitrust premerger notice. Larger deals can require a filing and a waiting period before closing. Read more at the FTC Premerger Notification Program.
- State healthcare transaction notice laws. A growing number of states require notice or review of healthcare deals, which can add time to the closing calendar.
- Federal referral and self-referral rules. Referral relationships, physician ownership and post-closing compensation all draw scrutiny. Ask your attorney how these rules apply to your deal. Read more at HHS OIG.
- Corporate practice of medicine and MSO structure. Many states limit who can own a medical practice, which shapes how PE buyers structure the deal. See our guide to management services organizations.
- Broker-dealer registration and how your advisor's fee is paid. Who can be paid a success fee on a company sale is a regulated question.
- Tax treatment of cash, rollover and earnout. Structure decides when and how each piece is taxed.
Our guides on physician investors who refer and the healthcare M&A process cover how these questions affect timing.
2026 Engagement-Letter Checklist for Physician Owners
Get written answers before you sign with any advisor.
| Term | What to ask | Seller-friendly position | Why |
|---|---|---|---|
| Buy-side history | Which platforms and sponsors has the firm represented as buyers, and which has it sold practices to more than once? | Full list disclosed in writing | An advisor's best long-term customers may be the buyers bidding for your practice |
| Dual representation | Will the firm represent, or take any fee from, the buyer in your deal? | No, stated in the letter | Split loyalty |
| Exclusivity and tail | How long is the exclusive term, how do you end it, and does a tail owe a fee if you later sell to a buyer the advisor contacted? | Short term, termination on notice, tail limited to buyers the advisor actively engaged and named in writing | A long, broad tail means paying an advisor you fired |
| Fee trigger and base | Is the fee triggered at signing, at closing or on cash received? Does it apply to rollover and maximum earnout at closing? Are retainers credited? | Fee on the closing price including escrow, then on earnout and rollover cash when received, retainers fully credited | In Offer A, rollover and maximum earnout are $3.90 million of the $12.00 million headline, 32.5% (our arithmetic). A fee on full headline at closing is partly paid on value you may never receive |
| Registration | Through which firm is the banker registered, and how will the success fee be paid? | Registration status confirmed in writing. If the firm and banker are registered, both show on FINRA BrokerCheck with any disclosures reviewed. Ask your attorney whether any registration exemption applies to your advisor | BrokerCheck is a free lookup of registration and disclosure history. Fee payment sits on the regulatory list above |
| Regulatory coordination | Will the firm work with your healthcare counsel from preparation onward? | Counsel involved before outreach | A late regulatory question delays closing and gives the buyer a reason to renegotiate |
| Escrow and RWI | Will the advisor push for RWI and a smaller holdback? | Yes, with RWI cost allocation negotiated | In SRS Acquiom's 2025 data, the median general indemnity escrow was 0.5% of transaction value with RWI and 10.0% without |
| Alignment of pay | For each advisor on your side, what event pays them? | Part of pay tied to cash you actually receive | An advisor paid only at closing has no stake in whether your earnout or rollover pays later |
Questions Practice Owners and Investors Ask
Do I need a sell-side advisor if a private equity platform approached me directly?
Not always. The practical case is strong in dental and outpatient care. In PESP's 2025 review, 95% of 149 tracked dental PE deals were add-ons by PE-owned platforms. Becker's ASC Review, reporting PESP's 2025 data, counted 119 add-ons among 148 outpatient deals. A PE buyer in those fields is often a platform buying an add-on, though national counts cannot show who your buyer is or how your local market works. Check how many deals it has announced. Then put a sell-side advisor or experienced healthcare deal counsel on your side before you sign an LOI with exclusivity.
Which healthcare specialties have the most buyers right now?
PESP counts deals, not buyers. In its 2025 review, dental care (149 deals) and outpatient care (148) were among the most active tracked PE healthcare segments. Within outpatient care, Becker's ASC Review, reporting PESP's 2025 data, put dermatology at 24 deals, eye care at 22 and oncology at 9. These are national counts. To gauge local demand, list the acquirers that closed deals in your specialty and state over the past 24 months. Then count the distinct buyers that could want your market.
Is healthcare M&A activity picking up in 2026?
For hospitals, yes. Becker's Hospital Review, reporting Kaufman Hall data, counted 22 hospital transactions in Q1 2026, 18 in Q2 and 16 in Q3, 56 in total, and reported that the year is on pace to be the busiest since the pandemic as megamergers mount. Kaufman Hall reported $8.2 billion of transacted revenue in Q3 2026 and an average seller size of nearly $586 million. On the PE side, Bain counted 445 global healthcare buyouts announced in 2025, the second most on record. Pricing is softer. PitchBook data reported by Sikich shows the median healthcare M&A multiple falling from 13x EV/EBITDA in 2025 to 11.6x for 2026 year to date as of Sikich's Q3 2026 update.
Sources
- CMS, National Health Expenditure fact sheet (2024 spending, 2025 to 2034 projections)
- Private Equity Stakeholder Project, Private Equity Healthcare Deals: 2025 in Review (calendar 2025, PitchBook and LevinPro HC data)
- Becker's ASC Review, The outpatient specialties that dominated 2025 deal activity (PESP 2025 outpatient data)
- Becker's Hospital Review, Hospital M&A on pace for busiest year since pandemic as megamergers mount (Kaufman Hall quarterly counts through Q3 2026)
- Kaufman Hall, Q3 2026 M&A Quarterly Activity Report release (Oct 13, 2026)
- SRS Acquiom, 2026 Deal Terms for M&A Escrows (private-target deals in SRS Acquiom's dataset, mainly 2025)
- SRS Acquiom, 2026 M&A Earnout and Milestone Trends (2025 private-target deals, with 2014 to 2022 comparisons)
- Sikich, Q3 2026 US healthcare M&A market update and year-end outlook (market multiples cite PitchBook)
- BuckheadFMV, Healthcare Services M&A Valuation Multiples 2023 to 2026 (187 U.S. control transactions, January 2023 to October 2026)
- Axia Growth, Physician Practice Management and MSOs (PAI-Avalere physician employment data as of January 1, 2026, closed-sale multiples as of October 28, 2026)
- Bain & Company, Global Healthcare Private Equity Report 2026 press release
- SEC EDGAR full-text search (securities offering notices and other public filings)
- FINRA BrokerCheck (firm and banker registration and disclosure history)
- FTC Premerger Notification Program
- HHS OIG, Fraud and abuse laws